Stanniocalcin-1 as a Diagnostic and Prognostic Biomarker in Papillary Thyroid  Carcinoma: A Comprehensive Review

Aml Mohamed Mohamed Fahym, Magdy Ismail Abdel-Reheim, Ola Abdelraouf Harb,  Hebatullah Abulkhair

Stanniocalcin-1 as a Diagnostic and Prognostic Biomarker in Papillary Thyroid Carcinoma: A Comprehensive Review

Authors

Aml Mohamed Mohamed Fahym, Magdy Ismail Abdel-Reheim, Ola Abdelraouf Harb, Hebatullah Abulkhair

Keywords:

Stanniocalcin-1, Diagnostic and Prognostic, Papillary Thyroid Carcinoma

Abstract

Papillary thyroid carcinoma (PTC) is the most prevalent subtype of thyroid cancer, accounting for themajority of endocrine malignancies. Despite its generally favorable prognosis, certain PTC cases exhibit aggressive clinical behavior, underlining the importance of identifying reliable biomarkers to refine diagnosis, risk stratification,and therapeutic decision-making. Stanniocalcin-1 (STC1),

References

Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054-1067.

Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-1348.

Downloads

Published

2024-06-20

How to Cite

Aml Mohamed Mohamed Fahym, Magdy Ismail Abdel-Reheim, Ola Abdelraouf Harb, Hebatullah Abulkhair. (2024). Stanniocalcin-1 as a Diagnostic and Prognostic Biomarker in Papillary Thyroid Carcinoma: A Comprehensive Review . Journal of Computational Analysis and Applications (JoCAAA), 33(06), 2652–2667. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3571